TKT Replagal Renal Function Trial To Be Submitted By Year-End

Transkaryotic Therapies will submit data from a Phase III trial evaluating renal function in Fabry disease patients treated with Replagal by the end of the year, CEO Richard Selden, MD/PhD, said Oct. 30